A PHASE 2, MULTICENTER, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE EFFECTS OF SOTATERCEPT FOR THE TREATMENT OF COMBINED POSTCAPILLARY AND PRECAPILLARY PULMONARY HYPERTENSION (CPC-PH) DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

Registry ID

MK-7962-023

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2026-04-22

Last update

2025-03-04

Conditions

• HEART FAILURE
• PULMONARY HYPERTENSION

Related clinical trials

• EFFICACY AND SAFETY OF NNC0487-0111 COMPARED TO PLACEBO ON MORBIDITY AND MORTALITY IN PEOPLE WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (HF-POLARIS)
• A MULTI-CENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR- BLINDED, PLACEBO-CONTROLLED CROSSOVER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HJB647 IN PARTICIPANTS WITH CHRONIC STABLE HEART FAILURE WITH REDUCED OR MILDLY REDUCED EJECTION FRACTION (HFREF/HFMREF)
• ORAL L-CARNITINE SUPPLEMENTATION IN CARDIORENAL HEART FAILURE PATIENTS
• A PHASE 2A, OPEN-LABEL, SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)
• A PHASE 3, SINGLE-ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF FINERENONE IN ADDITION TO STANDARD OF CARE, IN PEDIATRIC HEART FAILURE PATIENTS, FROM BIRTH TO 18 YEARS OF AGE, WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND PK/ PD OF FINERENONE, IN ADDITION TO STANDARD-OF-CARE, IN PEDIATRIC PATIENTS, 6 MONTHS TO < 18 YEARS OF AGE WITH HEART FAILURE (HF) AND LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)

View on source registry